 Globe and Mail |
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Newser The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based in Whitehouse Station, N.J … Merck tops view, newer drugs cushion asthma drug blow Merck posts mixed results for third quarter MERCK & CO., INC. : Merck 3rd-Quarter Profit Up 2.2%; Narrows Year View |
View full post on asthma – Google News